George Z Cheng

Dr. George Z Cheng

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2003
Verified
Journal Article
Closed access
TGTatiana M Gritsko
Tatiana M Gritsko
DCDomenico Coppola
Domenico Coppola
JPJune E Paciga
June E Paciga
LYLin Yang
Lin Yang
MSMei Sun
Mei Sun
George Z ChengGeorge Z Cheng
George Z Cheng

1 November 2003
Verified
Journal Article
Closed access
MFMichael Fraser
Michael Fraser
BLBrendan M Leung
Brendan M Leung
XYXiaojuan Yan
Xiaojuan Yan
HDHan C Dan
Han C Dan
George Z ChengGeorge Z Cheng
George Z Cheng
BTBenjamin K Tsang
Benjamin K Tsang

15 November 2003
Verified
Journal Article
Closed access
MSMadhavi Sekharam
Madhavi Sekharam
HZHaiyan Zhao
Haiyan Zhao
MSMei Sun
Mei Sun
QFQuan Fang
Quan Fang
QZQingbo Zhang
Qingbo Zhang
DCDomenico Coppola
Domenico Coppola

25 January 2024 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
AKAlexandra Kuhlmann-Hogan
Alexandra Kuhlmann-Hogan
TCThekla Cordes
Thekla Cordes
ZXZiyan Xu
Ziyan Xu
RKRamya S. Kuna
Ramya S. Kuna
KTKacie A. Traina
Kacie A. Traina
SKSusan M. Kaech
Susan M. Kaech
The limited efficacy of currently approved immunotherapies in EGFR-driven lung adenocarcinoma (LUAD) underscores the need to better understand alternative mechanisms governing local immunosuppression to fuel novel therapies. Elevated surfactant and GM-CSF secretion from the transformed epithelium induces tumor-associated alveolar macrophage (TA-AM) proliferation, which supports tumor growth by rewiring inflammatory functions and lipid metabolism. TA-AM properties are driven by increased GM-CSF–PPARγ signaling and inhibition of airway GM-CSF or PPARγ in TA-AMs suppresses cholesterol efflux to tumor cells, which impairs EGFR phosphorylation and restrains LUAD progression. In the absence of TA-AM metabolic support, LUAD cells compensate by increasing cholesterol synthesis, and blocking PPARγ in TA-AMs simultaneous with statin therapy further suppresses tumor progression and increases proinflammatory immune responses. These results reveal new therapeutic combinations for immunotherapy-resistant EGFR-mutant LUADs and demonstrate how cancer cells can metabolically co-opt TA-AMs through GM-CSF–PPARγ signaling to provide nutrients that promote oncogenic signaling and growth. Significance: Alternate strategies harnessing anticancer innate immunity are required for lung cancers with poor response rates to T cell–based immunotherapies. This study identifies a targetable, mutually supportive, metabolic relationship between macrophages and transformed epithelium, which is exploited by tumors to obtain metabolic and immunologic support to sustain proliferation and oncogenic signaling. This article is featured in Selected Articles from This Issue, p. 384

1 June 2020 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
George Z ChengGeorge Z Cheng
George Z Cheng
LLLihua Liu
Lihua Liu
MNMatthew Nobari
Matthew Nobari
RMRussell Miller
Russell Miller
MWMomen Wahidi
Momen Wahidi
Navigation bronchoscopy has reached a new horizon in its evolution. Combining with real-time imaging modalities, such as cone-beam computed tomography (CBCT) and augmented fluoroscopy (AF), navigation success can finally be confirmed with high degree of accuracy in real-time. With utilization of this modality, additional clinical observations are being made to help address the CT-body divergence problem and further improve navigation accuracy. This review focuses on description of CBCT navigation technique, provide tips on addressing CT-Body divergence, and review evidence for CBCT applications in navigation bronchoscopy.

1 August 2003
Verified
Journal Article
Closed access
TCTingan Chen
Tingan Chen
IYIvana Yang
Ivana Yang
RIRosalyn Irby
Rosalyn Irby
KSKenneth H Shain
Kenneth H Shain
Hong-Gang WangHong-Gang Wang
Hong-Gang Wang
TYTimothy J Yeatman
Timothy J Yeatman